Kazia Therapeutics (KZIA) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kazia Therapeutics announces organizational changes with the resignation of Gabrielle Heaton, Vice President of Finance and Administration, effective June 28, 2024, which is not due to any internal disagreements. Jeffrey Bonacorda has been appointed as the new Principal Accounting Officer and Principal Financial Officer starting July 1, 2024, bringing over 25 years of experience in various industries. Bonacorda’s appointment is part of the company’s strategic alignment and his annual salary will be $150,000.
For further insights into KZIA stock, check out TipRanks’ Stock Analysis page.